All In Biotech

Free tool

FAERS Monitor: Utebzi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215960 or its brand name (Utebzi, Tebipenem Pivoxil Hydrobromide). Reports on generic versions are filed under their own applications.

Reports

6

Serious

5

83% of reports

Hospitalization

3

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug interaction2
  • nausea2
  • anticonvulsant drug level below therapeutic1
  • bacterial pyelonephritis1
  • blood lactic acid increased1
  • cholangitis1
  • clostridium difficile infection1
  • coagulopathy1
  • disseminated intravascular coagulation1
  • drug level decreased1
  • epilepsy1
  • fatigue1
  • hypoproteinaemia1
  • liver abscess1
  • myringitis1

Reports by year received

View as table
YearReports
20153
20171
20211
20221

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,153 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myringitis148068.87915.011,854
bacterial pyelonephritis110474.71744.62,610
anticonvulsant drug level below therapeutic14666.3778.61,164
hypoproteinaemia11848.8308.7461
liver abscess11081.0180.6269
blood lactic acid increased1665.6111.2165
cholangitis1565.594.5140
drug level decreased1344.457.585
disseminated intravascular coagulation1249.141.661
coagulopathy1210.435.252
clostridium difficile infection1160.626.839
epilepsy1114.719.228
drug interaction244.214.347
nausea28.92.97
fatigue14.50.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.